Jessica Sachs Net Worth

Jessica Sachs biography

Dr. Jessica Sachs M.D. serves as Chief Medical Officer of the Company. Dr. Sachs has served as our Chief Medical Officer since June 2019. Prior to assuming the role of Chief Medical Officer at Unum, she served as Vice President of Clinical Sciences at Unum, responsible for the clinical development strategy and medical and translational oversight of the Unum portfolio. Before joining Unum, Dr. Sachs spent several years at Takeda/Millennium where she led multiple clinical programs in oncology and transplantation, and at Genzyme Corporation, where she was responsible for post-marketing safety surveillance and risk management activities for a variety of oncology products. Dr. Sachs has been a faculty member of the Harvard Medical School since 2007 and is an Assistant in Pediatrics in the Division of Pediatric Hematology/Oncology at the Massachusetts General Hospital. She completed her fellowship in pediatric hematology and oncology at the Dana Farber Cancer Institute and Children’s Hospital Boston. She received her M.D. from Washington University in St. Louis and her B.S. from Duke University.

How old is Jessica Sachs?

Jessica Sachs is 45, he's been the Chief Medical Officer of Unum Therapeutics since 2019. There are 3 older and 4 younger executives at Unum Therapeutics. The oldest executive at Unum Therapeutics, Inc. is Arlene Morris, 68, who is the Independent Director.

What's Jessica Sachs's mailing address?

Jessica's mailing address filed with the SEC is C/O UNUM THERAPEUTICS INC., 200 CAMBRIDGE PARK DRIVE, SUITE 3100, CAMBRIDGE, MA, 02140.

Insiders trading at Unum Therapeutics

Over the last 7 years, insiders at Unum Therapeutics have traded over 0$ worth of Unum Therapeutics stock and bought 1,283,156 units worth 11,122,392$ . The most active insiders traders include Llc Fmr、Liam Ratcliffe、Bruce Booth. On average, Unum Therapeutics executives and independent directors trade stock every 72 days with the average trade being worth of 286,216$. The most recent stock trade was executed by Healthcare Capital Partners... on 14 August 2020, trading 451,000 units of UMRX stock currently worth 1,136,520$.

What does Unum Therapeutics do?

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Unum Therapeutics executives and stock owners

Unum Therapeutics executives and other stock owners filed with the SEC include:

• Karen Ferrante,
  Independent Director
• Arlene Morris,
  Independent Director
• Matthew Ros,
  Independent Director
• Stephanie Ascher,
  Investor Relations
• Peter Harwin,
  Director
• Chris Cain,
  Director
• Jessica Sachs,
  Chief Medical Officer
• John Green,
  Chief Financial Officer, Vice President - Finance, Controller
• Andrew Robbins,
  President, Chief Executive Officer and Principal Executive Officer, Director
• Llc Fmr,
  
• Bruce Booth,
  Director
• Funds Management Llc Fairmount,
  10% owner
• Ltd Fil,
  
• Venture Fund Ix, L.P.Atlas ...,
  
• Liam Ratcliffe,
  Director
• Jorn Aldag,
  Director
• Robert J Perez,
  Director
• Seth Ettenberg,
  Chief Scientific Officer
• Geoffrey Hodge,
  Chief Technical Officer
• Charles Wilson,
  Chief Executive Officer
• Michael Vasconcelles,
  Chief Medical Officer
• Matthew Scott Osborne,
  Chief Financial Officer
• Healthcare Capital Partners...,